Mesoblast to Start Site Enrollment in Pivotal Trial for Cell Therapy Label Extension; Shares Fall 4%

MT Newswires Live11:13

Mesoblast (ASX:MSB) said a pivotal trial is expected to start site enrollment this quarter for the label extension of Ryoncil for use in adults with steroid-refractory acute graft-versus-host disease (SR-aGvHD), according to a Thursday filing with the Australian bourse.

Ryoncil is the company's mesenchymal stromal cell (MSC) therapy for the treatment of patients aged 2 months and older, including adolescents and teenagers, with SR-aGvHD.

Shares of the company fell nearly 4% in recent Thursday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2607776301?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-29 11:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607776301","market":"hk","top_or_hot":-1,"title":"Mesoblast to Start Site Enrollment in Pivotal Trial for Cell Therapy Label Extension; Shares Fall 4%","media":"MT Newswires Live","content":"<html><body><p> Mesoblast (ASX:MSB) said a pivotal trial is expected to start site enrollment this quarter for the label extension of Ryoncil for use in adults with steroid-refractory acute graft-versus-host disease (SR-aGvHD), according to a Thursday filing with the Australian bourse.</p><p>Ryoncil is the company's mesenchymal stromal cell (MSC) therapy  for the treatment of patients aged 2 months and older, including adolescents and teenagers, with SR-aGvHD.</p><p>Shares of the company fell nearly 4% in recent Thursday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast to Start Site Enrollment in Pivotal Trial for Cell Therapy Label Extension; Shares Fall 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast to Start Site Enrollment in Pivotal Trial for Cell Therapy Label Extension; Shares Fall 4%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-29 11:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Mesoblast (ASX:MSB) said a pivotal trial is expected to start site enrollment this quarter for the label extension of Ryoncil for use in adults with steroid-refractory acute graft-versus-host disease (SR-aGvHD), according to a Thursday filing with the Australian bourse.</p><p>Ryoncil is the company's mesenchymal stromal cell (MSC) therapy  for the treatment of patients aged 2 months and older, including adolescents and teenagers, with SR-aGvHD.</p><p>Shares of the company fell nearly 4% in recent Thursday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2607776301","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607776301","pubTimestamp":1769656406,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mesoblast  said a pivotal trial is expected to start site enrollment this quarter for the label extension of Ryoncil for use in adults with steroid-refractory acute graft-versus-host disease , according to a Thursday filing with the Australian bourse.Ryoncil is the company's mesenchymal stromal cell  therapy  for the treatment of patients aged 2 months and older, including adolescents and teenagers, with SR-aGvHD.Shares of the company fell nearly 4% in recent Thursday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","MSB.AU":"MESOBLAST LTD","BK7508":"医药生物股","BK7501":"新冠治疗股","MESO":"Mesoblast Limited","BK4575":"芯片概念","MSC":"新濠影汇","BK4150":"赌场与赌博","BK4139":"生物科技"},"translate_title":"Mesoblast将开始细胞治疗标签扩展关键试验的研究中心招募；股价下跌4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSC":1,"MSB.AU":1,"MESO":1.5},"content_text":"Mesoblast (ASX:MSB) said a pivotal trial is expected to start site enrollment this quarter for the label extension of Ryoncil for use in adults with steroid-refractory acute graft-versus-host disease (SR-aGvHD), according to a Thursday filing with the Australian bourse.Ryoncil is the company's mesenchymal stromal cell (MSC) therapy  for the treatment of patients aged 2 months and older, including adolescents and teenagers, with SR-aGvHD.Shares of the company fell nearly 4% in recent Thursday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607776301","isCrawlerRequest":true}